Treatment of Kaposi sarcoma-associated herpesvirus (KSHV)-associated cancers
Kaposi sarcoma (KS) is the most frequent AIDS-defining cancer worldwide. Kaposi sarcoma associated herpesvirus (KSHV) is the etiological agent of KS, and the virus is also associated with two lymphoproliferative diseases. Both KS and KSHV-associated lymphomas, are cancers of unique molecular compos...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2012-04-01
|
| Series: | Frontiers in Microbiology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fmicb.2012.00141/full |
| Summary: | Kaposi sarcoma (KS) is the most frequent AIDS-defining cancer worldwide. Kaposi sarcoma associated herpesvirus (KSHV) is the etiological agent of KS, and the virus is also associated with two lymphoproliferative diseases. Both KS and KSHV-associated lymphomas, are cancers of unique molecular composition. They represent a challenge for cancer treatment and an opportunity to identify new mechanisms of transformation. Here, we review the current clinical insights into KSHV-associated cancers and discuss scientific insights into the pathobiology of KS, primary effusion lymphoma and multicentric Castleman’s disease. |
|---|---|
| ISSN: | 1664-302X |